Skip to content
Scientific Resources

Articles & Key Literature

The peer-reviewed evidence behind organoid-based drug response profiling: the clinical studies that validated the approach, the biobanks that proved the platform, and the regulatory shift toward human-relevant models.

Clinical Validation

Organoids Predict How Patients Respond

Prospective and co-clinical studies comparing organoid drug responses with the treatment outcomes of the same patients. These are the trials that turned patient-derived organoids from a promising culture technique into a validated predictive platform.

Prospective trial

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Vlachogiannis G, Hedayat S, Vatsiou A, et al. · Science, 2018; 359(6378): 920–926

Organoids from 110 metastatic biopsies of patients in phase I/II trials mirrored the mutation spectrum and phenotype of the original tumors. Drug responses in the dish forecast responses in the clinic with 100% sensitivity, 93% specificity, 88% positive and 100% negative predictive value: the landmark demonstration that ex vivo organoid testing carries real clinical signal.

Read the paper →DOI: 10.1126/science.aao2774

Prospective trial

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Ooft SN, Weeber F, Dijkstra KK, et al. · Science Translational Medicine, 2019; 11(513): eaay2574

A prospective study showing that organoids generated from metastatic colorectal cancer biopsies predicted response to irinotecan-based chemotherapy in more than 80% of patients, without misclassifying any patient who would have benefited. A template for using organoids to spare non-responders ineffective treatment.

Read the paper →DOI: 10.1126/scitranslmed.aay2574

Co-clinical study

Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer

Yao Y, Xu X, Yang L, et al. · Cell Stem Cell, 2020; 26(1): 17–26

A living organoid biobank built alongside a phase III trial in locally advanced rectal cancer. Organoid responses matched patient chemoradiation outcomes with 84% accuracy (78% sensitivity, 92% specificity), supporting organoid testing as a companion tool for treatment stratification.

Read the paper →DOI: 10.1016/j.stem.2019.10.010

Co-clinical study

A rectal cancer organoid platform to study individual responses to chemoradiation

Ganesh K, Wu C, O’Rourke KP, et al. · Nature Medicine, 2019; 25(10): 1607–1614

Rectal cancer organoids retained the histopathology and genomic alterations of their matched tumors, and their ex vivo responses to chemotherapy and radiation paralleled patients’ progression-free survival: independent confirmation that organoid drug testing tracks clinical outcome.

Read the paper →DOI: 10.1038/s41591-019-0584-2

Systematic review

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Wensink GE, Elias SG, Mullenders J, et al. · npj Precision Oncology, 2021; 5: 30

A systematic review pooling the published evidence on organoid-based response prediction across tumor types, assessing analytical validity, clinical validity, and clinical utility. Useful as a single entry point into the predictive-biomarker literature this field is built on.

Read the paper →DOI: 10.1038/s41698-021-00168-1

Foundational Science

The Biobanks That Proved the Platform

The studies that established tumor organoids as faithful, expandable models: living biobanks across major solid-tumor indications showing that organoids preserve the histology, mutation spectrum, and drug-response heterogeneity of the tumors they came from.

Breast cancer

A living biobank of breast cancer organoids captures disease heterogeneity

Sachs N, de Ligt J, Kopper O, et al. · Cell, 2018; 172(1–2): 373–386

More than 100 primary and metastatic breast cancer organoid lines reproducing the genetic and pathological diversity of the disease, with organoid drug responses matching tumor subtype biology. Demonstrates that organoid panels can represent patient heterogeneity at scale.

Read the paper →DOI: 10.1016/j.cell.2017.11.010

Liver cancer

Human primary liver cancer–derived organoid cultures for disease modeling and drug screening

Broutier L, Mastrogiovanni G, Verstegen MMA, et al. · Nature Medicine, 2017; 23(12): 1424–1435

Organoids from the major primary liver cancer subtypes retained the histology and molecular features of their tissue of origin even in long-term culture, and drug screening on them surfaced a candidate therapeutic vulnerability: platform utility beyond the colorectal setting.

Read the paper →DOI: 10.1038/nm.4438

Reviews & Perspectives

Where the Field Stands

Authoritative reviews and perspectives from the laboratories that created organoid technology and shaped functional precision oncology, for readers who want the full scientific context in one sitting.

Perspective

Cancer modeling meets human organoid technology

Tuveson D, Clevers H. · Science, 2019; 364(6444): 952–955

A field-defining perspective from two pioneers of the technology on how self-organizing 3D cultures recapitulate the structure and function of the tissues they model, and what that means for cancer research and drug development.

Read the paper →DOI: 10.1126/science.aaw6985

Review

Organoids in cancer research

Drost J, Clevers H. · Nature Reviews Cancer, 2018; 18(7): 407–418

The standard review of organoid cancer models: why physiologically relevant 3D human models translate basic research into treatment regimens more efficiently than conventional systems, and where the technology is heading.

Read the paper →DOI: 10.1038/s41568-018-0007-6

Perspective

Functional precision cancer medicine—moving beyond pure genomics

Letai A. · Nature Medicine, 2017; 23(9): 1028–1035

The case for functional testing: genomics alone leaves most patients without an actionable match, while directly perturbing living tumor cells with candidate therapies yields decision-grade information. The conceptual backbone of functional precision oncology.

Read the paper →DOI: 10.1038/nm.4389

Regulatory Landscape

Regulators Are Moving the Same Way

Drug development no longer has to run through animal models by default. The regulatory ground is shifting toward human-relevant new approach methodologies, and organoids are named among them.

US legislation

FDA Modernization Act 2.0

United States Congress, S.5002, signed into law 29 December 2022 · Public Law 117-328

Removes the statutory requirement that new drugs be tested in animals before human trials, explicitly allowing alternatives including cell-based assays, organoids, organs-on-chips, and computational models to support investigational applications.

Read the paper →

Summaries on this page are provided for scientific reference and link to the original publications, which remain the authoritative source. External links lead to the respective publishers. 3DxCell services are for research use only.

Want to discuss the science behind your study? Contact us →